Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 168Recruiting 122Unknown 68Terminated 53Not yet recruiting 42Active not recruiting 18Withdrawn 8Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 35Breast Neoplasms 30Prostatic Neoplasms 21Colorectal Neoplasms 21Leukemia, Myeloid, Acute 19Pancreatic Neoplasms 17Melanoma 17Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 15Lung Neoplasms 13Brain Neoplasms 13Glioma 12Carcinoma, Hepatocellular 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Ovarian Neoplasms 9Multiple Myeloma 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Carcinoma, Renal Cell 8Rectal Neoplasms 6Leukemia 6Hematologic Neoplasms 6Esophageal Neoplasms 6Uterine Cervical Neoplasms 5Sarcoma 5Recurrence 5

Interventions

Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × Advanced Solid Tumors × Clear all
NCT01226056 2010-10-21

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Southern Europe New Drug Organization

Phase 1/2 Suspended
45 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡